Close
RNS Number : 6778C
Craneware plc
01 May 2026
 

1 May 2026

Craneware plc

("Craneware" or the "Company" or the "Group")

Transaction in Own Shares

 

 

Craneware (AIM: CRW.L), a leader in healthcare financial performance solutions, announces today it has purchased the following number of its Ordinary Shares of 1 pence each through Investec Bank plc ("Investec") in the period from 23 April 2026 to 29 April 2026.

The table below contains detailed information about the purchases made as part of the buyback programme which was announced by the Company on 16 March 2026 (the "Programme").

Date

Venue

Volume-weighted average price (p)

Aggregated volume

Lowest price per share (p)

Highest price per share (p)

23 April 2026

AIMX

1560.3572

23,815

1549.6000

1570.0000

23 April 2026

XLON

1551.6432

11,082

1546.0000

1560.0000

24 April 2026

AIMX

1557.1628

11,945

1557.0000

1558.0000

24 April 2026

XLON

1557.8857

10,463

1550.0000

1564.0000

27 April 2026

AIMX

1572.4885

26,040

1565.0000

1580.0000

27 April 2026

XLON

1572.2319

8,925

1558.0000

1588.0000

28 April 2026

AIMX

1537.4098

30,500

1530.0000

1540.0000

28 April 2026

XLON

1531.1221

12,109

1520.0000

1556.0000

29 April 2026

AIMX

1530.4206

34,787

1520.0000

1538.0000

29 April 2026

XLON

1531.3211

12,269

1518.0000

1556.0000

 

The Company intends to hold the purchased shares in Treasury.

 

Following the above transactions, the Company will hold 1,012,003 Ordinary Shares in Treasury and has 34,530,166 Ordinary Shares in issue (excluding Treasury shares).

 

The figure of 34,530,166 represents the total voting rights in the Company and may be used by shareholders as the denominator for calculating whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Individual Transactions

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014 as it forms part of UK law, a full breakdown of the individual trades made by Investec on behalf of the Company as part of the buyback programme is attached to this announcement.

http://www.rns-pdf.londonstockexchange.com/rns/6778C_1-2026-4-30.pdf

 

For further information please contact:

Craneware plc

+44 (0)131 550 3100

Keith Neilson, CEO


Craig Preston, CFO

 




Alma Strategic Communications

+44 (0)20 3405 0205

Caroline Forde, Kinvara Verdon, Louisa El-Ahwal

craneware@almastrategic.com





 

About Craneware

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in healthcare financial and operational transformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus® cloud ecosystem unifies data, revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance, improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster - that simplify the complexities of healthcare finance and operations. What sets us apart is our unique combination of deep healthcare expertise and engineering excellence, positioning us as a strategic partner rather than just a technology provider. The Craneware Group empowers healthcare organizations to achieve sustainable financial success while delivering better outcomes for the communities they serve - today and in the future. Together, we are transforming the business of healthcare.

 

Learn more at www.thecranewaregroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSWPUBGCUPQGQU